Tigecycline Dosing in Liver Impairment
Tigecycline, an IV glycylcycline antibiotic, requires dose adjustments in patients with moderate to severe hepatic impairment due to its primary hepatic metabolism and biliary excretion. No adjustment is needed for mild impairment (Child-Pugh A). For moderate (Child-Pugh B), use a 100 mg loading dose followed by 25 mg every 12 hours. For severe (Child-Pugh C), use the same reduced maintenance dose. These adjustments aim to prevent excessive drug accumulation, as clearance drops significantly in advanced liver disease.[1][2]
Safety Data from Clinical Studies
In trials, tigecycline showed higher mortality rates overall (4% vs. 3% in comparators), with some analyses linking this to hepatic adverse events like elevated liver enzymes or failure, though causality is unclear. Patients with baseline liver issues were included but monitored closely; discontinuation rates due to liver-related AEs were low (around 1-2%). Use caution in decompensated cirrhosis, as data is limited.[1][3]
When to Avoid or Monitor Closely
Avoid tigecycline in acute liver failure or end-stage liver disease without specialist oversight, due to risks of worsening hepatic encephalopathy or coagulopathy. Monitor liver function tests frequently, especially in Child-Pugh B/C patients. It's not recommended for pregnant patients with liver issues due to limited data. Concomitant hepatotoxins (e.g., acetaminophen) increase risks.[2][4]
Alternatives for Liver-Impaired Patients
For infections like complicated intra-abdominal or skin infections, consider alternatives with less hepatic dependence:
- Eravacycline: Similar mechanism, no dose adjustment for Child-Pugh B/C; FDA-approved for similar indications.
- Meropenem or piperacillin-tazobactam: Renal clearance primary; adjust for kidney issues instead.
- Daptomycin: For skin infections, minimal liver metabolism.
Consult ID specialist for resistance patterns; tigecycline retains utility in multidrug-resistant cases if monitored.[3][5]
[1]: Tigecycline Prescribing Information (FDA)
[2]: Drugs.com - Tigecycline Dosage in Hepatic Impairment
[3]: ClinicalTrials.gov - Tigecycline Studies (e.g., NCT00079599)
[4]: LiverTox - Tigecycline
[5]: IDSA Guidelines for Complicated Infections